KalVista Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de KalVista Pharmaceuticals es Ben Palleiko , nombrado en Mar 2024, tiene una permanencia de menos de un año. compensación anual total es $6.77M, compuesta por 8.6% salario y 91.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.62% de las acciones de la empresa, por valor de $3.08M. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 3.7 años, respectivamente.
Información clave
Ben Palleiko
Chief Executive Officer (CEO)
US$6.8m
Compensación total
| Porcentaje del salario del CEO | 8.6% |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.6% |
| Permanencia media de la dirección | 2.4yrs |
| Promedio de permanencia en la Junta Directiva | 3.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
Sep 12
KalVista Pharmaceuticals: Looking To Be A Major Player In HAE
Sep 05Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
Jun 24KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Feb 14We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Jan 30We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Oct 04We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
May 02KalVista: Another Setback But The Key Value Driver Is Still In Place
Oct 14Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
Sep 24KalVista Pharmaceticals GAAP EPS of -$0.94
Sep 08KalVista reaches five-month high as rival tumbles on hereditary angioedema
Aug 22KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11
Jul 07Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
May 18Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth
Feb 02We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed
Sep 24We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely
Jul 02Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | -US$142m |
| Apr 30 2024 | US$7m | US$580k | -US$127m |
| Jan 31 2024 | n/a | n/a | -US$108m |
| Oct 31 2023 | n/a | n/a | -US$101m |
| Jul 31 2023 | n/a | n/a | -US$95m |
| Apr 30 2023 | US$2m | US$515k | -US$93m |
| Jan 31 2023 | n/a | n/a | -US$91m |
| Oct 31 2022 | n/a | n/a | -US$92m |
| Jul 31 2022 | n/a | n/a | -US$89m |
| Apr 30 2022 | US$3m | US$490k | -US$82m |
| Jan 31 2022 | n/a | n/a | -US$73m |
| Oct 31 2021 | n/a | n/a | -US$61m |
| Jul 31 2021 | n/a | n/a | -US$52m |
| Apr 30 2021 | US$1m | US$435k | -US$46m |
| Jan 31 2021 | n/a | n/a | -US$38m |
| Oct 31 2020 | n/a | n/a | -US$37m |
| Jul 31 2020 | n/a | n/a | -US$33m |
| Apr 30 2020 | US$1m | US$435k | -US$29m |
| Jan 31 2020 | n/a | n/a | -US$31m |
| Oct 31 2019 | n/a | n/a | -US$26m |
| Jul 31 2019 | n/a | n/a | -US$23m |
| Apr 30 2019 | US$2m | US$366k | -US$21m |
| Jan 31 2019 | n/a | n/a | -US$13m |
| Oct 31 2018 | n/a | n/a | -US$14m |
| Jul 31 2018 | n/a | n/a | -US$16m |
| Apr 30 2018 | US$821k | US$340k | -US$16m |
Compensación vs. Mercado: La compensación total de Ben($USD6.77M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.14M).
Compensación vs. Ingresos: La compensación de Ben ha aumentado mientras la empresa no es rentable.
CEO
Ben Palleiko (58 yo)
less than a year
Permanencia
US$6,772,197
Compensación
Mr. Benjamin L. Palleiko, also known as Ben, has been Director and Chief Executive Officer of KalVista Pharmaceuticals, Inc. from March 07, 2024. He served as President of KalVista Pharmaceuticals, Inc. fr...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | less than a year | US$6.77m | 0.62% $ 3.1m | |
| Chief Development Officer | 9yrs | US$1.37m | 0.21% $ 1.0m | |
| Chief Medical Officer | 3.5yrs | US$1.83m | 0.22% $ 1.1m | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| General Counsel | no data | sin datos | sin datos | |
| Vice President of Corporate Communications | no data | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs & QA | no data | sin datos | sin datos | |
| Senior Vice President of Development | 5.5yrs | sin datos | sin datos | |
| Chief Commercial Officer | 1.3yrs | sin datos | sin datos | |
| Director of Finance and Company Secretary | no data | sin datos | sin datos |
2.4yrs
Permanencia media
51yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de KALV se considera experimentado (2.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | less than a year | US$6.77m | 0.62% $ 3.1m | |
| Independent Director | 9.9yrs | US$136.60k | 0% $ 0 | |
| Independent Chairman | 5.8yrs | US$161.60k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$136.60k | 0% $ 0 | |
| Independent Director | less than a year | US$143.78k | sin datos | |
| Board Observer | 9.3yrs | sin datos | sin datos | |
| Independent Director | 2.5yrs | US$124.10k | 0% $ 0 |
3.7yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de KALV se considera experimentada (3.7 años de antigüedad promedio).